AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04443309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 8mg (\<60kg) or 12mg (≥60kg),po,d2,qd
Study NCT03460561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural block (TEA)
Description: Under complete aseptic precautions and before induction of GA, thoracic epidural catheter was inserted using a 17 gauge, Tuohy epidural needle by a midline approach. T9-T10 interspace was chosen for the injection after skin infiltration by 5 mL of lidocaine 1%. The epidural space was identified by the loss of resistance technique then the catheter was introduced 2 cm into the epidural space, and epidural test dose of 3 mL of lidocaine 2% with 1:200,000 adrenaline was injected to exclude vascular or subarachnoid position.
Study NCT03460561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus sheath block (RSB)
Description: Under aseptic technique, the rectus muscle was imaged with the ultrasound probe, A broadband (5-12 MHz) linear array probe of Sonosite ™ 3000 ultrasound (FUJIFILM, Sonosite EDGE II -UAS) in a transverse orientation at or immediately above the level of the umbilicus, with an imaging depth of 4-6 cm.~Inserting the needle: An 18G Tuohy needle was introduced few millimeters from the probe using an in plane technique in an angle of 45 degrees to the skin. (posterior rectus sheath and fascia transversalis). Under direct vision, the needle tip was advanced to the desired position where 20 mL of (levo-bupivacaine 0.25% Fentanyl 30 μg) were injected causing hydro dissection of the rectus muscle away from the posterior rectus sheath. The technique is repeated on the opposite side.
Study NCT03964324 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fractioned Exhaled Nitrogen Oxide measurements
Description: Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
Study NCT02355210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacteria adolescentis BD1
Description: packet containing 10\^9 cells of Bifidobacteria adolescentis BD1
Study NCT02355210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacteria animalis subsp. lactis BB-12
Description: packet containing 10\^9 cells of Bifidobacteria animalis subsp. lactis BB-12
Study NCT02355210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacteria adolescentis BD1 and galactooligosaccharide
Description: packet containing 10\^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
Study NCT00847951 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3D Ultrasound Imaging
Description: Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys in pre-mature and/or very low birth weight babies. This is a measure of perfusion and an indication of how well the kidneys are working.
Study NCT03613766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Study NCT00561912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 15 mg/m\^2 IV Daily over one hour for 5 days
Study NCT00561912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: 0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
Study NCT01640249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally
Study NCT01640249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3006072
Description: Capsules administered orally
Study NCT03673917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: The educational video on skin cancer for cosmetologists
Study NCT03673917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control video
Description: A publicly accessible healthy lifestyle video on YouTube, which does not contain any information on skin cancer
Study NCT03390335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure
Description: Subjects undergo altitude exposure, diving exposure, and return to altitude. Altitudes: 8,000, 10,000, 12,000, or 15,000 feet Dives: 60 or 100 feet of sea water
Study NCT03390335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Gas
Description: Subjects will breathe air, 35% Oxygen, Balance Nitrogen, or 100% Oxygen during the diving exposure
Study NCT02591524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar and Nasal Lavage
Description: A previously scheduled flexible bronchoscopy via the nasal route on the date of baseline visit combined with a nasal lavage and another nasal lavage after 6 month
Study NCT01804179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunochemical Fecal Occult Blood Test (I-FOBT) Kit
Description: Participants will receive an Immunochemical Fecal Occult Blood Test (I-FOBT) Kit (a home stool blood test) used as a first-step screening tool for colorectal cancer to take home. The research staff will provide instructions on how to use the kit.
Study NCT01804179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunochemical Fecal Occult Blood Test (I-FOBT) Kit
Description: Participants will receive an Immunochemical Fecal Occult Blood Test (I-FOBT) Kit (a home stool blood test) used as a first-step screening tool for colorectal cancer to take home. The research staff will provide instructions on how to use the kit.
Study NCT01804179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intervention (SI) Educational Materials
Description: Screen for Life brochure
Study NCT01804179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CARES Intervention Educational Materials
Description: Newly developed digital video disc (DVD) and booklet
Study NCT02355210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide
Description: packet containing 10\^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide
Study NCT02355210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: galactooligosaccharide
Description: 5 g galactooligosaccharide
Study NCT02440256 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Expanded HIV care in Opioid Substitution Treatment
Description: The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.
Study NCT03473275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cold Pressor test
Description: Both feet in icy waterbath alternated with body temperature water
Study NCT03473275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PinPrick test
Description: Pricking both feet with a needle using gravity (without penetrating) alternated with cotton swap
Study NCT03385447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants underwent 12-weeks of exercise prescription aimed at the federal guidelines (3 days/week).
Study NCT06212596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumour suppressor proteins (TSPs). Selinexor is an oral, first-in-class, potent, slowly reversible, covalent-binding Selective Inhibitor of Nuclear Export (SINE) compound that specifically blocks the karyopherin protein Exportin 1 (XPO1), also called chromosome region maintenance 1.
Study NCT06212596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a long used conventional chemotherapy with potent anti-myeloma activity and low toxicity when administered at low doses as in the current protocol (Hajek et al. (2016)). It is being extensively used in combination with novel agents, including bortezomib, lenalidomide, and pomalidomide, and provides a cost-effective and well-tolerated alternative as a combination partner (Morgan et al. (2007); Mai et al. (2015); Baz et al. (2016)).
Study NCT06212596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a long used conventional chemotherapy with potent anti-myeloma activity and low toxicity when administered at low doses as in the current protocol (Hajek et al. (2016)). It is being extensively used in combination with novel agents, including bortezomib, lenalidomide, and pomalidomide, and provides a cost-effective and well-tolerated alternative as a combination partner (Morgan et al. (2007); Mai et al. (2015); Baz et al. (2016)).
Study NCT06212596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Steroids have been a very effective backbone for every myeloma combination therapy developed so far. Prednisone is the standard steroid in a number of widely used regimens (Mateos et al. (2010);Palumbo et al. (2006)). Decreasing the morbidity associated with high dose steroid use by using better-tolerated regimens addresses a large unmet need of the myeloma patient population.
Study NCT06212596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Steroids have been a very effective backbone for every myeloma combination therapy developed so far. Prednisone is the standard steroid in a number of widely used regimens (Mateos et al. (2010);Palumbo et al. (2006)). Decreasing the morbidity associated with high dose steroid use by using better-tolerated regimens addresses a large unmet need of the myeloma patient population.
Study NCT02923349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01949
Description: Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
Study NCT03187704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HEPA air filtration
Description: Air filters were placed in participant homes
Study NCT03187704 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: HEPA air filtration
Description: Air filters were placed in participant homes
Study NCT01653925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention first
Description: The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids. Three consultations with a nutritionist experienced in clinical trials will be planned over a 6-month period. An additional 2 consultations in the last 6 months with the study nutritionist will be planned for men allocated to the dietary fat intervention arm first. Then, after the 6 months of diet intervention, drug intervention with 5α-Reductase Inhibitor will be add to diet for the 6 following months.
Study NCT01653925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug (Dutasteride) intervention first
Description: 5α-Reductase Inhibitor will be taken daily in tablet dosage form (0.5 mg) taken orally for 12 months depend of the group. After 6 months of drug intake, dietary fat intervention will be add to treatment for the following 6 months. Three consultations with a nutritionist experienced in clinical trials will be planned over this 6-month period.
Study NCT00886548 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound performed
Description: Nurse-driven ultrasound performed
Study NCT01294644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection
Study NCT01294644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study NCT01492127 — intervention group
Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Blood test
Description: Blood test
Study NCT03784222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blonanserin
Description: patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability
Study NCT03784222 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI and serum BDNF
Description: 60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test
Study NCT03784222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI and serum BDNF
Description: 60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test
Study NCT00835328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.
Study NCT00835328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.
Study NCT02827110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic bronchoscope
Description: Tracheal intubation using fiberoptic bronchoscope
Study NCT02827110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope
Description: Tracheal intubation using fiberoptic bronchoscope
Study NCT02827110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pentax-airway scope
Description: Tracheal intubation using pentax-AWS
Study NCT02827110 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: semi-rigid collar
Description: semi-rigid collar immobilization of the cervical spine
Study NCT02827110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: semi-rigid collar
Description: semi-rigid collar immobilization of the cervical spine
Study NCT03130946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-assisted core needle biopsy
Description: Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.
Study NCT03130946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FNA
Description: FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
Study NCT03699774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a
Description: DS-8500a is provided as three 25-mg tablets for oral administration
Study NCT03699774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin is provided as a 10-mg tablet for oral administration
Study NCT01609049 — intervention group
Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: Administration of treatment will be according to local recommendation under local labeling.
Study NCT01609049 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
Study NCT02980211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alveolar Ridge Reconstruction
Description: Reconstruction of dehiscence defects in extraction sockets with a minimally invasive technique using a particulate bone allograft and a non-absorbable dense polytetrafluoroethylene (dPTFE) membrane
Study NCT04322552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib at a dosage of will be administered daily from on D5 through D16
Study NCT04322552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet
Description: Digoxin at a dosage of 0.25mg will be administered at day 1 and day 12
Study NCT04162873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO or via feeding tube
Study NCT03130946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FNA
Description: FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
Study NCT00623714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: fluticasone
Description: Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
Study NCT04162873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO or via feeding tube
Study NCT04162873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04162873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04162873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04162873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05070182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: REE - Resting Energy Expenditure
Description: REEs represent 60-70% of the needs for a sedentary person and 50% of physically active people.~For the measurement of REE will be used the metabolic computer (Medical Graphics, Ultima CCM, Minneapolis, USA), which with continuous recording of breath-to-breath volume (Vt), respiratory rate (RR) of ventilation per minute volume (MV) ), of inhaled and exhaled gases (O2 and CO2) has the ability to calculate the values of VO2, VCO2 and with the help of equations the values of REE and RQ.~All patients in the study will be monitored with the metabolic computer. Their measurements will be recorded every day during their stay in the ICU.
Study NCT05070182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler
Description: The measurement of flow velocities in the middle cerebral artery will be done with the transcranial Doppler using a low frequency (2 MHz) ultrasound head.~All patients entering the study will be examined with the TCD every day during their stay in the ICU.
Study NCT04584827 — intervention group
Intervention type: OTHER
Intervention: lactate level
Description: Lactate, a byproduct of glycolysis, is an indicator of weak tissue perfusion and a useful biomarker with prognostic value in various diseases. Lactate value is calculated by blood gas.
Study NCT04584827 — intervention group
Intervention type: OTHER
Intervention: Glasgow Outcome Scale
Description: Glasgow Outcome Scale; It is a scale developed to categorize people suffering from head trauma or non-traumatic acute brain injury into broad outcome categories. It shows postoperative mortality and morbidity of patients who underwent intracranial surgery.
Study NCT01002573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Ibuprofen, 10 mg/kg
Study NCT01002573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: Acetaminophen, 10mg/kg
Study NCT03196401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: durvalumab 1500mg administered intravenously every 28 days, for a total of six doses
Study NCT03196401 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting
Study NCT03434665 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transradial celiac artery angiography
Description: * After completion of transradial diagnostic coronary angiography and/or PCI, before removal of the radial arterial sheath, selective angiography of the celiac artery will be performed.~* Technically, a 0.35-inch wire is advanced into the descending aorta. A 125 cm 5-French Judkins right catheter is inserted over this wire, which is then removed. The distal tip of the catheter is brought in front of the ostium of the celiac artery and positioning is confirmed with angiography of the celiac artery. Two or three views will be obtained to determine the optimal view to visualize the left gastric artery anatomy. All material is removed and hemostasis is obtained as per clinical routine for coronary angiography.
Study NCT00920166 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pétunia 1
Description: Infant formula used for non breastfed children
Study NCT00920166 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular formula
Description: Infant formula used for non breastfed children
Study NCT01189201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773/linagliptin
Description: medium single dose of BI 10773/linagliptin FDC (Formulation A1)
Study NCT01189201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773/linagliptin
Description: medium single dose of BI 10773/linagliptin FDC (Formulation A3)